Tissue repair and performance — what exists, what doesn't, what is banned

Quick answer

Four peptide families circulate as "recovery" and tissue-repair agents: the gastric pentadecapeptide BPC-157, native thymosin-β4 and its synthetic fragment TB-500, and the copper tripeptide GHK-Cu. Each has its own mechanism: BPC-157 modulates gastroprotective and angiogenic pathways via Akt-eNOS; Tβ4 sequesters G-actin and mobilizes tissue progenitors; GHK-Cu modulates collagen and cutaneous angiogenesis. Published human literature in 2026 is uneven: Tβ4 has a phase 2 in venous ulcer (n=73) and a phase 3 in neurotrophic keratopathy (n=18); BPC-157 has three small pilots with no phase 3 RCT; TB-500 has no published human RCT; GHK-Cu has clinical evidence in dermatology, not in musculoskeletal recovery. WADA prohibits BPC-157, TB-500, and Tβ4. None of the four has ANVISA approval for recovery in healthy adults.

Why this guide exists

Search on peptides for tissue repair and performance runs into two opposite sources. On one side, "research peptide" catalogs and bodybuilding forums presenting BPC-157, TB-500, and combinations as consolidated solutions for injury recovery and performance. On the other, dense academic literature that separates peptides into silos without connecting the landscape. What's missing is editorial synthesis describing mechanism, real human evidence, and Brazilian regulatory status for the four leading names in this pillar.

This guide is that synthesis. It does not direct doses, recommend protocols, or advise intervention. It describes what exists in indexed literature as of April 2026, and where the gaps sit. The canonical Portuguese fact-sheets at /peptideos/bpc-157, /peptideos/tb-500, /peptideos/timosina-beta-4, and /peptideos/ghk-cu carry the molecule-level detail.

The underlying question: what is "tissue repair" as a pharmacological target?

Tissue repair in humans involves reasonably well-characterized biological phases — hemostasis, inflammation, cell proliferation, and remodeling — orchestrated by dozens of endogenous growth factors and cytokines. Under localized injury, the system works; healing occurs within timeframes set by tissue physiology.

The pharmacological hypothesis behind regenerative peptides is different: that exogenous peptides with regulatory activity — pro-angiogenic, pro-migratory, anti-inflammatory — can accelerate or complete repair in situations where the endogenous system cannot do it alone. Slow-healing tendon injury. Chronic non-closing ulcer. Persistent corneal epithelial defect. Postoperative knee.

The operational question is not whether the hypothesis is plausible — it is. The question is how large the effect is in humans, in which indication, at which dose, with which safety profile under prolonged use. The answer varies dramatically across the four peptides discussed in this guide.

Mechanisms: four classes, four entry points

Each of the four peptides acts through a distinct mechanism. Understanding this distinction is the key to not treating "BPC-157", "TB-500", "Tβ4", and "GHK-Cu" as if they were interchangeable variants of a single intervention.

BPC-157 — synthetic gastric pentadecapeptide

BPC-157 is a 15-amino-acid peptide derived from a partial fragment of human gastric protein, synthesized and developed by Predrag Sikiric's group at the University of Zagreb. Preclinical literature describes modulation of pathways related to:

• Angiogenesis via VEGFR2 and nitric oxide (Akt-eNOS axis).
• Gastroprotective activity — capacity to protect gastric mucosa from aggressors such as NSAIDs, alcohol, and stress.
• Tendon, ligament, and bone repair in animal injury models.
• Protection of surgical anastomoses in rats.

Preclinical work is largely from the original Croatian group — over 80% of PubMed-indexed publications on BPC-157 come from that group. Independent replication in published human trials is essentially nonexistent.

Thymosin-β4 — native regulatory peptide

Thymosin-β4 is a natural peptide of 43-44 amino acids, described by Goldstein in 1981, and the principal G-actin sequesterer in mammals. Mechanisms relevant to repair are:

• Cytoskeletal modulation via G-actin sequestration — basis for cell motility regulation.
• Stimulation of keratinocyte, fibroblast, and endothelial cell migration in healing models.
• Angiogenesis via VEGF and related factors.
• Mobilization of epicardial progenitors in a murine infarct model (Smart 2007, Nature).
• Anti-inflammatory and antifibrotic action in multiple preclinical models.

The central region of the molecule (residues 17-23, sequence LKKTETQ) is the active actin-binding site. This sequence is exactly reproduced in the synthetic fragment TB-500.

TB-500 — acetylated synthetic fragment of Tβ4

TB-500 is the heptapeptide Ac-LKKTETQ corresponding to residues 17-23 of thymosin-β4. It is not the same molecule — it is a fragment. Definitive chemical characterization was carried out by Esposito 2012 (PMID 22962027), confirming that commercial products labeled "TB-500" contain the fragment, not the native molecule.

The mechanistic hypothesis is that the fragment preserves the pro-healing activity of native Tβ4 by reproducing the actin-binding site. In vitro studies describe cell migration and angiogenic modulation. Recent analyses suggest part of the pro-healing activity attributed to TB-500 may be mediated by its metabolite Ac-LKKTE rather than the intact native molecule.

Human literature specific to TB-500 in clinical trials is essentially nonexistent in 2026. Most indexed literature on the peptide is in preclinical models and equine veterinary pharmacology.

GHK-Cu — copper tripeptide

GHK-Cu is the tripeptide Glycyl-Histidyl-Lysine complexed with copper ion (Cu2+). It was isolated in 1973 by Loren Pickart from human albumin, in a study showing that the fraction containing the tripeptide induced aged hepatic tissue to synthesize proteins like young tissue. Mechanisms described in preclinical and dermatological clinical literature include:

• Stimulation of collagen and elastin synthesis in cutaneous fibroblasts.
• Modulation of metalloproteinases (MMPs) and tissue inhibitors (TIMPs).
• Cutaneous angiogenesis with neocapillary formation.
• Local anti-inflammatory activity.
• Antioxidant activity via copper complexation.

A peculiarity of GHK-Cu is that endogenous plasma levels drop with age — Pickart and colleagues reported approximately 200 ng/mL at age 20 vs ~80 ng/mL at age 60. The therapeutic hypothesis was historically replacement of regenerative cutaneous activity lost with aging.

The most robust human clinical evidence for GHK-Cu is in dermatology: topical cosmetic products with ANVISA registration, clinical case series in diabetic ulcer, post-laser resurfacing recovery. In injectable systemic musculoskeletal recovery, there is no published human RCT.

The hierarchy of human evidence in 2026

The difference between these four peptides is not just in mechanism — it is in the quantity and quality of human evidence each accumulates. The editorial table is simple and hard.

Native thymosin-β4 — the only one with a published phase 3

It has two published human trials in indexed journals with structured clinical formulation:

• Guarnera 2010 (PMID 20536470, NCT00382174) — multicenter phase 2 in venous stasis ulcer, n=73 randomized, 8 European sites. Topical Tβ4 vs placebo, safety profile comparable to placebo, ~25% complete healing at 3 months.
• Sosne 2023 (PMID 36613994, NCT02600429) — multicenter phase 3 in neurotrophic keratopathy, n=18 (10 RGN-259 0.1% ophthalmic vs 8 placebo). Complete healing in 60% of active arm vs 12.5% placebo at day 29 (p=0.0656); significant difference at day 43 (p=0.0359). The subsequent European trial (SEER-3) did not meet its primary endpoint.

These are the human trials with the greatest structure published — placebo-controlled, multicenter, registered on ClinicalTrials.gov. Real limitations: modest sample sizes and restricted indications (venous ulcer, keratopathy). There is no published phase 3 in musculoskeletal recovery.

BPC-157 — three small pilots, zero phase 3

The Vasireddi 2025 systematic review (PMID 40756949) identified a single human study in orthopedic sports medicine — Lee 2021, a retrospective review of 17 people with knee pain receiving intra-articular BPC-157. It reported relief in 14 of 16 reached at follow-up, without a control arm and without blinding.

The McGuire 2025 narrative review (PMID 40789979) identified three human pilots in total: the knee one (Lee 2021), a series in interstitial cystitis, and the IV safety pilot in 2 people (Lee 2025).

The largest historical gap is the PLIVA phase 2 trial (PL 14736 enema in mild-to-moderate ulcerative colitis), conducted in the 2000s and never published in an indexed peer-reviewed journal. That trial would have been the formal test of the founding hypothesis — gastrointestinal healing in humans. The results are not available to the scientific community.

The conclusion of both 2025 reviews is the same: BPC-157 should be considered investigational.

TB-500 — zero published human RCT

Human literature specific to TB-500 (Ac-LKKTETQ) in clinical trials is essentially nonexistent in indexed journals as of 2026. Published studies on TB-500 itself concentrate on:

• Chemical characterization and analytical methods for doping control (Esposito 2012, Ho 2012).
• Animal preclinical models.
• Equine veterinary pharmacology.

Commercial catalogs frequently cite native thymosin-β4 studies (Smart 2007 in heart, Sosne in cornea, Goldstein in hair follicle) as if they were evidence for TB-500. Pharmacologically, it is not the same compound. Editorially, the transposition is not defensible.

GHK-Cu — robust in dermatology, absent in systemic recovery

It has published human clinical evidence in topical formulation for:

• Photoaged skin — multiple clinical case series and registered cosmetic products.
• Diabetic ulcer — diabetic foot series with positive signal.
• Post-laser resurfacing recovery — series in facial plastic surgery.
• Post-Mohs surgery — documented use.

A regulatory peculiarity is that GHK-Cu is widely marketed as a cosmetic ingredient in topical formulations with ANVISA registration. That is a regulatory terrain distinct from injectable "research peptide".

In systemic musculoskeletal injectable recovery — where GHK-Cu appears in "research peptide" catalogs — published human literature is essentially absent in 2026. Transposing dermatological topical evidence to systemic muscle recovery is not supported by any human RCT.

Regulatory status in Brazil

ANVISA (Brazil's federal drug regulatory agency) has no marketing authorization for medicines containing BPC-157, TB-500, or thymosin-β4 (Tβ4) for use in humans in Brazil. There is no industrialized product available for prescription as an approved medicine.

GHK-Cu is widely registered as a cosmetic ingredient in topical formulations — a regulatory terrain distinct from injectable medicine. For use in injectable formulations outside cosmetics, GHK-Cu falls into the same category as the others: a peptide unregistered as a medicine, compoundable only under medical prescription in a magistral pharmacy with sanitary licensing.

Technical Note No. 200/2025/SEI/GIMED/GGFIS/DIRE4/ANVISA, focused on peptide APIs, consolidates quality criteria applicable by extension to all four peptides when compounded:

• HPLC/UV identification.
• Mass peptide mapping.
• Assay by validated method.
• Impurity analysis (including truncated peptides and dimers).
• Sterility and endotoxins for injectable dosage form.
• Origin from supplier with audited chain.

Importation by individuals for self-administration is prohibited for inputs without registration in a sanitary reference country accepted by ANVISA. Purchases on international websites that sell peptides as "research grade" constitute irregular importation.

ANVISA has recorded, throughout 2025-2026, enforcement actions on irregular commercialization of compounded peptides, focused on pharmacies without licensing for hormones and biologicals and on supply chains without auditing.

WADA and sport

The World Anti-Doping Agency 2026 Prohibited List classifies the peptides discussed in this guide in two sections:

• S0 (Non-Approved Substances) — any pharmacological substance not addressed by subsequent sections of the List and without approval by any governmental health authority for current human therapeutic use. BPC-157 falls explicitly under this section.
• S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — growth factors and peptides affecting protein synthesis or degradation in muscle, tendon, or ligament, vascularization, or regenerative capacity. BPC-157, TB-500, and thymosin-β4 fall here. TB-500 and Tβ4 were formally added in 2011, after detections in equestrian sport.

The ban applies in and out of competition. There is no recognized TUE (Therapeutic Use Exemption) for these substances. Athletes in federations signatory to the World Anti-Doping Code with a positive test face automatic suspension.

GHK-Cu is not nominally listed on the WADA 2026 List. Topical cosmetic use in registered products is broadly permitted. For injectable use in compounded formulations — a situation in regulatory grey zone in Brazil — athletes should confirm with their federation's anti-doping agency before any use, since WADA interpretation of unlisted substances may evolve.

Where human evidence actually supports intervention

The 2026 clinical literature authorizes intervention in scenarios much more restricted than "recovery peptide" marketing suggests:

• Ophthalmic Tβ4 (RGN-259) in neurotrophic keratopathy — in clinical development, no regulatory approval yet, trials with positive signal limited by small sample.
• Topical GHK-Cu in photoaged skin and selected chronic ulcers — cosmetic formulation with ANVISA registration, consolidated evidence in dermatology.
• Recombinant GH in confirmed GH deficiency — outside the scope of this guide; see /guias/eixo-gh.

Outside these scenarios, clinical literature does not authorize intervention with BPC-157, TB-500, systemic injectable Tβ4, or systemic GHK-Cu in "recovery", anti-aging, or performance in healthy adults. There is no published multicenter phase 3 trial for these indications.

What we know

1. Native thymosin-β4 has positive trial signal in two narrow indications (venous ulcer, neurotrophic keratopathy) with sample sizes of 73 and 18.
2. BPC-157 has extensive preclinical literature concentrated in one research group; human evidence is limited to three small uncontrolled pilots.
3. TB-500 has no published human RCT specific to the heptapeptide Ac-LKKTETQ.
4. GHK-Cu has consolidated dermatological evidence in topical formulation; systemic injectable use lacks human trials.
5. WADA bans BPC-157, TB-500, and Tβ4 in and out of competition (sections S0 and S2).
6. ANVISA holds no marketing authorization for any of these peptides as injectable medicines for tissue repair in healthy people.

What we don't yet know

• Long-term safety profile of BPC-157 in humans across any indication.
• Whether TB-500 reproduces the in vivo activity of native Tβ4 in clinical outcomes.
• Whether the "BPC-157 + TB-500" combination (the so-called "wolverine stack") produces effects beyond placebo — no published human RCT exists.
• Whether systemic injectable GHK-Cu has any added effect over the topical formulation outside dermatology.
• Pharmacokinetics and biodistribution of these peptides in humans across different routes (subcutaneous, intra-articular, intravenous).
• Long-term oncological and immunological risk under repeated use.

When it makes sense to ask the doctor about regenerative peptides

pephealth does not direct intervention. For someone researching peptides starting from a commercial catalog, forum, or informal recommendation, bringing concrete questions to the medical visit makes a difference:

• What is the proposed indication, and what is the human clinical evidence specific to that indication?
• What is the source of the input — which compounding pharmacy, which supply chain, which certificate of analysis per batch?
• What are the route, dose, and duration — and on which human clinical evidence does this protocol rest?
• What is the monitoring plan for efficacy and safety?
• Which alternatives with greater evidence base have been considered?
• What is the WADA status of this intervention, if relevant to athletes?

Editorial closing

Tissue repair with peptides is a field where the biological hypothesis is elegant and preclinical literature is robust. Human clinical literature, however, is uneven and modest. In 2026, only native thymosin-β4 has randomized, multicenter, placebo-controlled human trials published in indexed journals — in two specific indications (venous ulcer, neurotrophic keratopathy), with small samples and no regulatory approval yet.

BPC-157 has three small human pilots, zero phase 3, and the phase 2 trial that could have tested the founding hypothesis (PL 14736 in colitis) was never published. TB-500 has zero specific human RCTs — all relevant clinical evidence is from the parent molecule Tβ4. GHK-Cu has a solid base in topical dermatology but zero RCTs in systemic musculoskeletal recovery.

The four peptides circulate in parallel markets and in compounded formulations under medical prescription. Three are banned by WADA. None has ANVISA, FDA, or EMA approval for "recovery" or anti-aging in healthy adults.

pephealth neither recommends nor discourages interventions with regenerative peptides. The function of this guide is to describe, with transparency about what does and does not exist in the 2026 clinical literature, the terrain where the conversation between the person who researches and the person who prescribes needs to happen.

Absence of data is not evidence of safety, nor evidence of efficacy. It is exactly that: absence of data. Naming that gap aloud is the central editorial point.